Abstract
1752
Objectives To assess safety and efficacy of 177Lu-EDTMP in bone pain palliation in breast and prostate cancer patients with bone metastases.
Methods Subjects were treated with 177Lu-EDTMP. Criteria for entry into the trial was a positive 99mTc-MDP bone scan consistent with bony metastase pain.Life expectancy is more than 3mo.
Results Eleven patients, 6 prostate and 5 breast cancer, aged 65.5±13.8yr (38-84 yr). Seven and four were received 1295 MBq (35mCi) and 2590MBq(70mCi) respectively. 11 patients mean bone lesion score was 14.18 (6-19). In platelet toxicity, 2(18%) of 11 patients developed grade I, 1(9%) developed grade III, 1(9%) developed grade IV. The mean nadir platelet count was 91,1111/mm3at the 4th wk and began to completely recovery from 6th wk; 1(9%) patient developed grade II leucocyte toxicity.The median nadir leucocyte counts was 4,352/mm3 at 2th wk and began to completely recovery from 6th wk. Two subjects did not provide the hematologic counts from 2th wk. Large dose caused more marrow suppression. Table 1 detailed all 11 patients responding almost at 2th wk by the observed trend of pain score, analgesic frequency, mobility, Kamofsky performance. Six, three and two of 11 patients had a duration of palliation of 3, 2, and 1 mo respectively.
Conclusions This primarily trial indicated that 177Lu-EDTMP is an effective treatment for palliation of pain from bony metastases. More cases are now being recruited into this study to further examine the efficacy of 177Lu-EDTMP.
Research Support IAEA.CRP.E1.30.33,No.1526
Table 1. Observed efficacy of 177Lu-EDTMP during 3 months following up
n:patients number;wk:week
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.